ALLERGAN AUSTRALIA PTY LIMITED

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Long-term 24-month Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 (Sodium Deoxycholate Injection)

Completed

Conditions: Subcutaneous Fat

Interventions: Drug: Deoxycholic acid Injection
Drug: Placebo

First Posted Date: 2018-09-24

Last Posted Date: 2018-09-24

Lead Sponsor: Allergan

Target Recruit Count: 201

Registration Number: NCT03682471

Locations: 🇩🇪
Licca Clinical Research Institute, Augsburg, Germany
🇩🇪
Dr. Beatrice Gerlach, Dresden, Germany
🇩🇪
Hautarztpraxis Cutanis, Freiburg, Germany

and more 15 locations

XEN-45 Gel Stent Versus Trabeculectomy in Glaucoma: Gold-Standard Pathway Study (GPS)

Phase 4

Completed

Conditions: Glaucoma

Interventions: Procedure: Trabeculectomy
Device: XEN-45 Gel Stent

First Posted Date: 2018-08-31

Last Posted Date: 2022-07-21

Lead Sponsor: Allergan

Target Recruit Count: 158

Registration Number: NCT03654885

Locations: 🇺🇸
Wills Eye Institute /ID# 233645, Philadelphia, Pennsylvania, United States
🇺🇸
Houston Eye Associates /ID# 233621, Houston, Texas, United States
🇺🇸
Nashville Vision Associates /ID# 233644, Nashville, Tennessee, United States

and more 32 locations

Clinical Trial Evaluation of a Test Serum Post HEV (High Energy Visible) Light Exposure

Not Applicable

Completed

Conditions: Blue Light Damage

Interventions: Other: Marvel AM

First Posted Date: 2018-07-20

Last Posted Date: 2018-09-07

Lead Sponsor: Allergan

Target Recruit Count: 12

Registration Number: NCT03594721

Locations: 🇺🇸
McDaniel Institute of Anti Aging Research, Virginia Beach, Virginia, United States

Efficacy, Safety, and Tolerability of Levomilnacipran ER in Pediatric Patients (7-17 Years) With Major Depressive Disorder

Phase 3

Completed

Conditions: Major Depressive Disorder

Interventions: Drug: Levomilnacipran ER
Drug: Placebo
Drug: Fluoxetine

First Posted Date: 2018-06-26

Last Posted Date: 2022-03-25

Lead Sponsor: Allergan

Target Recruit Count: 501

Registration Number: NCT03569475

Locations: 🇺🇸
Manhattan Behavioral Medicine, PLLC, New York, New York, United States
🇺🇸
AMR Conventions Limited, Naperville, Illinois, United States
🇺🇸
AMR-Baber Research, Inc., Naperville, Illinois, United States

and more 48 locations

Study to Evaluate Efficacy and Tolerability of Two Topical Regimens in Subjects With Moderate to Severe Facial Photodamage Who Have Received Cosmetic Injections

Not Applicable

Completed

Conditions: Facial Photodamage

Interventions: Other: on-label facial injection

First Posted Date: 2018-06-18

Last Posted Date: 2019-01-30

Lead Sponsor: Allergan

Target Recruit Count: 40

Registration Number: NCT03559972

Locations: 🇺🇸
Suzanne Bruce and Associates, PA, The Center for Skin Research, Houston, Texas, United States
🇺🇸
Cosmetic Laser Dermatology, San Diego, California, United States

A Study to Evaluate Abicipar Pegol for Safety and Treatment Effect in Participants With Neovascular Age-related Macular Degeneration (AMD)

Phase 2

Completed

Conditions: Macular Degeneration

Interventions: Drug: Abicipar pegol

First Posted Date: 2018-05-29

Last Posted Date: 2020-08-03

Lead Sponsor: Allergan

Target Recruit Count: 124

Registration Number: NCT03539549

Locations: 🇺🇸
Retina Consultants of Orange County, Fullerton, California, United States
🇺🇸
N. California Retina Vitreous Associates Medical Group, INC., Mountain View, California, United States
🇺🇸
Georgia Retina, P.C., Marietta, Georgia, United States

and more 34 locations

Safety and Effectiveness of JUVÉDERM® VOLBELLA® With Lidocaine for Lip Enhancement in Chinese Adults

Not Applicable

Completed

Conditions: Lip Enhancement

Interventions: Device: JUVÉDERM® VOLBELLA® XC with Lidocaine
Other: No-treatment Control

First Posted Date: 2018-05-08

Last Posted Date: 2019-08-06

Lead Sponsor: Allergan

Target Recruit Count: 176

Registration Number: NCT03519204

Locations: 🇨🇳
Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China
🇨🇳
Peking University Third Hospital, Beijing, China
🇨🇳
General Hospital of Southern Theatre Command, Guangzhou, Guangdong, China

and more 2 locations

Eluxadoline Bile Acid Malabsorption (BAM) Study

Phase 4

Completed

Conditions: Irritable Bowel Syndrome With Diarrhea

Interventions: Drug: Eluxadoline

First Posted Date: 2018-02-22

Last Posted Date: 2021-05-19

Lead Sponsor: Allergan

Target Recruit Count: 24

Registration Number: NCT03441581

Locations: 🇺🇸
Mayo Clinic, Rochester, Minnesota, United States

A Study of the Safety and Effectiveness of JUVÉDERM VOLUMA® XC Injectable Gel for Cheek Augmentation Using Cannula

Not Applicable

Completed

Conditions: Age-related Volume Deficit in the Mid-face

Interventions: Device: JUVÉDERM VOLUMA® XC injectable gel with cannula
Device: JUVÉDERM VOLUMA® XC injectable gel with needle

First Posted Date: 2018-02-19

Last Posted Date: 2019-08-05

Lead Sponsor: Allergan

Target Recruit Count: 66

Registration Number: NCT03438266

Locations: 🇺🇸
Art of Skin MD, Solana Beach, California, United States
🇺🇸
Baumann Cosmetic and Research Institute, Miami, Florida, United States
🇺🇸
Rhoda S. Narins, MD, PC, White Plains, New York, United States

and more 4 locations

Safety and Effectiveness of JUVÉDERM® VOLUMA® With Lidocaine for Improvement of Volume and Aesthetic Appearance of the Nose in Chinese Adults

Not Applicable

Completed

Conditions: Nose Enhancement

Interventions: Device: JUVÉDERM® VOLUMA® with Lidocaine
Other: No-treatment control

First Posted Date: 2018-02-13

Last Posted Date: 2020-12-30

Lead Sponsor: Allergan

Target Recruit Count: 164

Registration Number: NCT03430986

Locations: 🇨🇳
Union Hospital Tongji Medical College, Huazhong University of Science and Technology, Beijing, Wuhan, China
🇨🇳
Shanghai Sixth People's Hospital, Shanghai, Shanghai, China
🇨🇳
Peking University Third Hospital, Beijing, Beijing, China

and more 2 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy